Monitoring Tolerance, Safety and Acceptance of Depo-Eligard® in an Open Label, Retrospective, Non-interventional Clinical Trial
The study will provide data on the tolerance, safety and acceptance of Depo-Eligard®
(leuproreline acetate) when used in routine clinical practice. Data on efficacy parameters
such as testosterone, PSA levels, symptoms and treatment failure, if available will be
collected.It will reflect the way Depo-Eligard® is used in routine clinical practice and how
PSA, testosterone levels, symptoms and treatment failure, are used as parameters in the
treatment for Prostate Cancer.
Patient data will be collected after a treatment period of six months.
Observational Model: Cohort, Time Perspective: Retrospective
Tolerance, Safety (Adverse drug reactions, overall evaluation of safety and tolerability) and Acceptance of Depo-Eligard®
After at least 6 months treatment with Depo-Eligard
Use Central Contact
Astellas Pharma Europe BV
Belgium: Institutional Review Board